Neuberger Berman Group LLC Makes New Investment in Revvity, Inc. (NYSE:RVTY)

Neuberger Berman Group LLC acquired a new position in shares of Revvity, Inc. (NYSE:RVTYFree Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 14,568 shares of the company’s stock, valued at approximately $1,592,000.

Other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. bought a new position in Revvity in the third quarter valued at approximately $1,579,487,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Revvity in the 4th quarter valued at approximately $188,368,000. Norges Bank bought a new position in shares of Revvity in the fourth quarter valued at $129,483,000. Dimensional Fund Advisors LP acquired a new position in Revvity during the fourth quarter worth $112,037,000. Finally, Ceredex Value Advisors LLC bought a new stake in Revvity during the fourth quarter worth $108,353,000. Institutional investors own 86.65% of the company’s stock.

Wall Street Analyst Weigh In

RVTY has been the topic of several recent analyst reports. TD Cowen boosted their price objective on shares of Revvity from $123.00 to $130.00 and gave the stock a “buy” rating in a research note on Tuesday, April 30th. Stifel Nicolaus upped their price objective on Revvity from $95.00 to $110.00 and gave the company a “hold” rating in a research note on Friday, February 2nd. KeyCorp raised their price objective on Revvity from $110.00 to $126.00 and gave the company an “overweight” rating in a research report on Friday, February 2nd. Robert W. Baird boosted their target price on Revvity from $126.00 to $127.00 and gave the stock an “outperform” rating in a report on Tuesday, April 30th. Finally, Raymond James raised their price target on Revvity from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Six investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $118.17.

Check Out Our Latest Stock Analysis on Revvity

Revvity Price Performance

RVTY stock opened at $113.27 on Monday. The company’s 50-day moving average price is $104.74 and its two-hundred day moving average price is $102.94. The firm has a market cap of $13.98 billion, a P/E ratio of 93.61, a P/E/G ratio of 2.94 and a beta of 1.09. The company has a quick ratio of 1.92, a current ratio of 2.23 and a debt-to-equity ratio of 0.40. Revvity, Inc. has a 12 month low of $79.50 and a 12 month high of $131.96.

Revvity (NYSE:RVTYGet Free Report) last announced its quarterly earnings data on Monday, April 29th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.94 by $0.04. The business had revenue of $649.90 million during the quarter, compared to the consensus estimate of $646.83 million. Revvity had a net margin of 5.49% and a return on equity of 7.37%. The company’s revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.01 earnings per share. On average, analysts anticipate that Revvity, Inc. will post 4.66 earnings per share for the current fiscal year.

Revvity Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 9th. Stockholders of record on Friday, July 19th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Friday, July 19th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.25%. Revvity’s dividend payout ratio (DPR) is currently 23.14%.

About Revvity

(Free Report)

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.

Read More

Want to see what other hedge funds are holding RVTY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revvity, Inc. (NYSE:RVTYFree Report).

Institutional Ownership by Quarter for Revvity (NYSE:RVTY)

Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.